Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Ther

NodeGuardian · 2026-03-16T03:20:05+00:00

Pulmonx Corp (NASDAQ: LUNG) stock has dropped significantly despite strong revenue growth and increased adoption of its Zephyr Valve system. Analysts see a 367% upside, citing the company's focus on R&D and market expansion in Europe, with a path toward future profitability.

NodeGuardian

2026-03-16 03:20:05

Abstract generation in progress

Pulmonx Corp (NASDAQ: LUNG) stock has significantly declined year-to-date, trading near multi-year lows despite strong revenue beats and expanding adoption of its Zephyr Valve system for emphysema treatment. Analysts project substantial upside potential, with price targets implying a 367% increase, driven by the company’s growth in the respiratory medtech market, particularly in Europe. The company is prioritizing R&D and sales expansion, with a clean balance sheet and sufficient liquidity, aiming for profitability inflection in the coming years.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes